Survival analyses were conducted to evaluate the impact of ZIP4, ZIP7, and ZIP6 expression on both overall survival (OS) and relapse-free survival (RFS) in breast and colon cancers. This evidence concerns the gene SLC39A7 and malignant colon neoplasm.